Enhancing tumor immunity via in vivo cDC1 reprogramming.

IF 13.1 1区医学 Q1 IMMUNOLOGY

Trends in Immunology Pub Date : 2024-11-21 DOI:10.1016/j.it.2024.11.008

Yoojung Kwon, Kyunghee Choi

引用次数: 0

Abstract

A recent study by Ascic et al. demonstrates that in situ reprogramming of tumor cells into conventional dendritic cell (cDC)-like cells using viral-PIB transcription factors creates an immunogenic tumor microenvironment with T cell recruitment and activation. The study highlights the potential of tumor-specific cancer immunotherapy using in vivo reprogrammed cDCs.

查看原文本刊更多论文

通过体内 cDC1 重编程增强肿瘤免疫力。

Ascic等人最近的一项研究表明，利用病毒-PIB转录因子将肿瘤细胞原位重编程为传统树突状细胞（cDC）样细胞，可创造一种具有T细胞招募和活化功能的免疫原性肿瘤微环境。该研究强调了利用体内重编程 cDCs 进行肿瘤特异性癌症免疫疗法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in Immunology 医学-免疫学

CiteScore

25.10

自引率

0.60%

发文量

130

审稿时长

6-12 weeks

期刊介绍： Trends in Immunology serves as a vital platform for tracking advancements across various areas of immunology, offering concise reviews and hypothesis-driven viewpoints in each issue. With additional sections providing comprehensive coverage, the journal offers a holistic view of immunology. This broad perspective makes it an invaluable resource for researchers, educators, and students, facilitating the connection between basic and clinical immunology. Recognized as one of the top monthly review journals in its field, Trends in Immunology is highly regarded by the scientific community.